ImmunovantInc Non Current Assets Total vs Cash Analysis
IMVT Stock | USD 27.17 0.58 2.09% |
ImmunovantInc financial indicator trend analysis is infinitely more than just investigating ImmunovantInc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ImmunovantInc is a good investment. Please check the relationship between ImmunovantInc Non Current Assets Total and its Cash accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.
Non Current Assets Total vs Cash
Non Current Assets Total vs Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ImmunovantInc Non Current Assets Total account and Cash. At this time, the significance of the direction appears to have almost identical trend.
The correlation between ImmunovantInc's Non Current Assets Total and Cash is 0.93. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Cash in the same time period over historical financial statements of ImmunovantInc, assuming nothing else is changed. The correlation between historical values of ImmunovantInc's Non Current Assets Total and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of ImmunovantInc are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Non Current Assets Total i.e., ImmunovantInc's Non Current Assets Total and Cash go up and down completely randomly.
Correlation Coefficient | 0.93 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Cash
Cash refers to the most liquid asset of ImmunovantInc, which is listed under current asset account on ImmunovantInc balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from ImmunovantInc customers. The amounts must be unrestricted with restricted cash listed in a different ImmunovantInc account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most indicators from ImmunovantInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmunovantInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.At this time, ImmunovantInc's Tax Provision is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 78.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 30.1 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 156.0M | 208.3M | 239.5M | 123.8M | Research Development | 101.8M | 160.3M | 184.3M | 98.9M |
ImmunovantInc fundamental ratios Correlations
Click cells to compare fundamentals
ImmunovantInc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ImmunovantInc fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 109.4M | 412.5M | 515.6M | 405.8M | 466.7M | 264.7M | |
Total Current Liabilities | 15.3M | 18.8M | 44.5M | 43.3M | 49.8M | 52.3M | |
Total Stockholder Equity | 94.1M | 391.5M | 469.8M | 362.5M | 416.9M | 241.3M | |
Net Tangible Assets | 94.1M | 391.5M | 469.8M | 362.5M | 416.9M | 242.7M | |
Accounts Payable | 1.2M | 2.4M | 18.6M | 1.4M | 1.6M | 1.5M | |
Common Stock Shares Outstanding | 43.2M | 87.8M | 109.7M | 123.1M | 141.5M | 148.6M | |
Other Stockholder Equity | 185.3M | 590.4M | 824.8M | 928.0M | 1.1B | 1.1B | |
Total Liab | 15.3M | 21.0M | 45.7M | 43.3M | 49.8M | 52.3M | |
Total Current Assets | 109.1M | 409.0M | 512.9M | 404.3M | 465.0M | 263.2M | |
Short Long Term Debt Total | 3.2M | 3.4M | 2.4M | 1.2M | 1.4M | 2.3M | |
Other Current Liab | 14.1M | 15.2M | 24.7M | 40.8M | 46.9M | 49.2M | |
Property Plant And Equipment Net | 65K | 3.5M | 2.6M | 1.5M | 1.7M | 1.7M | |
Net Debt | (97.4M) | (396.7M) | (491.5M) | (375.3M) | (337.8M) | (354.7M) | |
Retained Earnings | (91.2M) | (198.7M) | (355.4M) | (566.3M) | (509.7M) | (484.2M) | |
Cash | 100.6M | 400.1M | 493.8M | 376.5M | 433.0M | 301.7M | |
Non Current Assets Total | 311K | 3.5M | 2.6M | 1.5M | 1.7M | 1.8M | |
Cash And Short Term Investments | 100.6M | 400.1M | 493.8M | 376.5M | 433.0M | 301.7M | |
Net Receivables | 3.0M | 548K | 12.9M | 885K | 1.0M | 966.9K | |
Common Stock Total Equity | 5K | 10K | 12K | 13K | 15.0K | 8.9K | |
Liabilities And Stockholders Equity | 109.4M | 412.5M | 515.6M | 405.8M | 466.7M | 317.6M | |
Non Current Liabilities Total | 14.1M | 2.2M | 1.2M | 47K | 42.3K | 40.2K | |
Capital Surpluse | 185.3M | 590.4M | 824.8M | 928.0M | 1.1B | 556.3M | |
Other Current Assets | 5.5M | 8.3M | 6.3M | 26.9M | 31.0M | 32.5M | |
Net Invested Capital | 94.1M | 391.5M | 469.8M | 362.5M | 416.9M | 290.0M | |
Capital Stock | 5K | 10K | 12K | 13K | 15.0K | 8.9K | |
Net Working Capital | 93.8M | 390.2M | 468.4M | 361.0M | 415.2M | 288.9M | |
Short Term Debt | 3.2M | 1.2M | 1.1M | 1.2M | 1.1M | 1.1M | |
Common Stock | 5K | 10K | 12K | 13K | 15.0K | 8.9K | |
Property Plant Equipment | 65K | 201K | 330K | 333K | 383.0K | 216.3K |
ImmunovantInc Investors Sentiment
The influence of ImmunovantInc's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in ImmunovantInc. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to ImmunovantInc's public news can be used to forecast risks associated with an investment in ImmunovantInc. The trend in average sentiment can be used to explain how an investor holding ImmunovantInc can time the market purely based on public headlines and social activities around ImmunovantInc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ImmunovantInc's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ImmunovantInc's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average ImmunovantInc's news discussions. The higher the estimated score, the more favorable is the investor's outlook on ImmunovantInc.
ImmunovantInc Implied Volatility | 105.13 |
ImmunovantInc's implied volatility exposes the market's sentiment of ImmunovantInc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if ImmunovantInc's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that ImmunovantInc stock will not fluctuate a lot when ImmunovantInc's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ImmunovantInc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ImmunovantInc's short interest history, or implied volatility extrapolated from ImmunovantInc options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for ImmunovantInc Stock analysis
When running ImmunovantInc's price analysis, check to measure ImmunovantInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunovantInc is operating at the current time. Most of ImmunovantInc's value examination focuses on studying past and present price action to predict the probability of ImmunovantInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunovantInc's price. Additionally, you may evaluate how the addition of ImmunovantInc to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is ImmunovantInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunovantInc. If investors know ImmunovantInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunovantInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.81) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of ImmunovantInc is measured differently than its book value, which is the value of ImmunovantInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunovantInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunovantInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunovantInc's market value can be influenced by many factors that don't directly affect ImmunovantInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunovantInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunovantInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunovantInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.